CCS
TECH icon

Crosspoint Capital Strategies’s Bio-Techne TECH Stock Holding History

Crosspoint Capital Strategies’s Portfolio TECH Stock Details TECH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-400
Closed -$9K – 625
2014
Q1 		$9K Buy
+400
New +$9K ﹤0.01% 488

Other funds holding TECH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $10.9B AUM 27.5% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Crosspoint Capital Strategies's TECH Position: Q2 2014 in Review

Crosspoint Capital Strategies sold out of Bio-Techne (TECH) in Q2 2014, closing a stake of 400 shares — an estimated $9K sold.

Crosspoint Capital Strategies first reported a position in TECH in Q1 2014 and held it in 1 quarter. The position peaked at $9K in Q1 2014. 237 funds tracked by Wall St. Rank hold TECH as of Q2 2014.

  • Crosspoint Capital Strategies reported no remaining Bio-Techne position as of Q2 2014 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 400 Bio-Techne shares in Q2 2014, an estimated $9K.
  • Crosspoint Capital Strategies first reported a position in Bio-Techne in Q1 2014 and held it in 1 quarter.
  • Crosspoint Capital Strategies's Bio-Techne position peaked at $9K in Q1 2014.
  • 237 funds tracked by Wall St. Rank held Bio-Techne as of Q2 2014.

Based on Crosspoint Capital Strategies's 13F filing for Q2 2014, filed 29 Jul 2014.